BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 39,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 39,000 shares of the business’s stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00. Following the completion of the transaction, the chief executive officer directly owned 341,209 shares in the company, valued at approximately $33,776,278.91. This represents a 10.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.

BioNTech Trading Up 0.8%

Shares of BNTX traded up $0.80 during trading hours on Thursday, hitting $99.26. 787,100 shares of the stock traded hands, compared to its average volume of 1,098,895. The business has a fifty day moving average of $97.88 and a 200-day moving average of $94.78. The firm has a market capitalization of $25.10 billion, a PE ratio of -12.68 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same period in the prior year, the firm posted ($1.60) earnings per share. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. Analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in BNTX. Larson Financial Group LLC grew its stake in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech during the second quarter worth about $39,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after purchasing an additional 506 shares in the last quarter. Vestcor Inc bought a new position in shares of BioNTech during the 4th quarter valued at about $153,000. Finally, Rockefeller Capital Management L.P. grew its position in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after purchasing an additional 1,423 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the subject of a number of analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. Citigroup cut their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Finally, Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.